10 completed, 1 not yet recruiting. 5 Not applicable, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 4, Not yet recruiting 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow levomefolate calcium: new trials by email Literature Review of levomefolate calcium trials Research Report on levomefolate calcium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of High-dose Folic Acid Supplementation on Pathways Linked to DNA Formation Folic acid, 5-methyltetrahydrofolate, calcium salt - One-carbon Metabolism in Healthy Individuals | Not applicable | Not yet recruiting | University of British Columbia | 25 | 2024-01-01 | 2023-08-15 |
| Natural Folate vs. Synthetic Folic Acid in Pregnancy Folic acid, (6S)-5-methyltetrahydrofolic acid - Pregnancy | Not applicable | Completed | University of British Columbia | 60 | 2019-09-16 | 2023-04-14 |
| Relative Bioavailability of Folic Acid and L-5-Methlytetrahydrofolate L-5-methyltetrahydrofolate (Metafolin ®), folic acid, Placebo - Vitamin B12 Deficiency | Not applicable | Completed | University of British Columbia | 150 | 2012-05-01 | 2012-08-10 |
| Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078), Estradiol Valerate (EV) (BAY86-4980), Levomefolate Calcium (BAY86-7660) - Contraception, Ovulation Inhibition | Phase 1 | Completed | Bayer | 42 | 2009-12-01 | 2014-02-20 |
| Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium, BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG), BAY 86-7660,levomefolate calcium - Pharmacology, Clinical | Phase 1 | Completed | Bayer | 43 | 2009-09-01 | 2016-08-01 |
| Assessment of the Pharmacodynamic Effect on Plasma Folate and Red Blood Cell Folate and Comparison of the Folate Metabolites During the 24 Weeks of Treatment (Yasmin + Metafolin Versus Yasmin + Folic Acid) Followed by a 20 Week Elimination Phase of Folate EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo, EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid - Contraception | Phase 1 | Completed | Bayer | 172 | 2006-12-01 | 2013-09-20 |
| Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss Fragmin P Forte (dalteparin sodium), Multivitamin supplement - Abortion, Habitual | Phase 3 | Completed | University of Jena | 449 | 2006-11-01 | 2014-09-17 |
| Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: YAZ and YAZ + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and YAZ + Levomefolate Calcium (Metafolin) EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300), EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca), L-5-MTHF 0.451mg (Metafolin) - Contraception | Phase 1 | Completed | Bayer | 44 | 2006-10-01 | 2013-08-07 |
| Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin) EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131), EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca), L-5-MTHF Ca 0.451 mg (Metafolin) - Contraception | Phase 1 | Completed | Bayer | 48 | 2006-08-01 | 2013-08-07 |
| Dietary Supplements for the Treatment of Angelman Syndrome Betaine, Creatine, Metafolin - Angelman Syndrome, Nervous System Diseases | Not applicable | Completed | University of California, San Diego | 90 | 2006-07-01 | 2012-09-24 |
| Increasing Folate Status of a General Population(FOLSUPP STUDY) Folic acid (supplement), Metafolin (supplement), Placebo - Healthy | Not applicable | Completed | Quadram Institute Bioscience | 180 | 2005-05-01 | 2015-03-24 |
Abortion, Habitual (1) · Angelman Syndrome (1) · Ataxia (1) · Intellectual Disability (1) · Learning Disabilities (1) · Microcephaly (1) · Nervous System Diseases (1) · Seizures (1) · Vitamin B 12 Deficiency (1)
Bayer (5) · University of British Columbia (3) · Quadram Institute Bioscience (1) · University of California, San Diego (1) · University of Jena (1)
Germany (5) · Canada (3) · Austria (1) · Malaysia (1) · Netherlands (1) · United Kingdom (1) · United States (1)
Arthur L. Beaudet, MD (1) · Carlos A. Bacino, MD (1) · Crystal Karakochuk, PhD (1) · Ekkehard Schleussner, Prof. Dr. (1) · Hilary Powers, BSc PhD (1) · Lynne M. Bird, MD (1) · Paul M Flingas, BSc (1) · Steven A. Skinner, MD (1) · Tim Green, PhD (1) · Wen-Hann Tan, BMBS (1) · Yvonne Lamers, PhD (1)
PMID 22002941, PMID 22067789, PMID 22909145, PMID 23610531, PMID 25938990, PMID 27418639, PMID 29878267, PMID 31640736, PMID 32370802, PMID 33779986, PMID 35687377
2005 (2), 2009 (2)